keyword
MENU ▼
Read by QxMD icon Read
search

ARB safety

keyword
https://www.readbyqxmd.com/read/27920760/prevalence-of-the-antibiotic-resistance-genes-in-coagulase-positive-and-negative-staphylococcus-in-chicken-meat-retailed-to-consumers
#1
Kamelia Osman, Jihan Badr, Khalid S Al-Maary, Ihab M I Moussa, Ashgan M Hessain, Zeinab M S Amin Girah, Usama H Abo-Shama, Ahmed Orabi, Aalaa Saad
The use of antibiotics in farm management (growing crops and raising animals) has become a major area of concern. Its implications is the consequent emergence of antibiotic resistant bacteria (ARB) and accordingly their access into the human food chain with passage of antibiotic resistance genes (ARG) to the normal human intestinal microbiota and hence to other pathogenic bacteria causative human disease. Therefore, we pursued in this study to unravel the frequency and the quinolone resistance determining region, mecA and cfr genes of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S...
2016: Frontiers in Microbiology
https://www.readbyqxmd.com/read/27875922/no-substantial-gender-differences-in-suspected-adverse-reactions-to-ace-inhibitors-and-arbs-results-from-spontaneous-reporting-system-in-campania-region
#2
Liberata Sportiello, Concetta Rafaniello, Maria Giuseppa Sullo, Mihaela Nica, Cristina Scavone, Francesca Futura Bernardi, Delia Maria Colombo, Francesco Rossi
BACKGROUND: Today, there is a poor knowledge about gender differences in adverse drug reactions (ADRs) to cardiovascular drugs such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Therefore, the aim of this study was to analyze spontaneous reports of suspected ADRs induced by ACE-inhibitors and ARBs, between January 2001 and June 2015, recorded in a Region of Southern Italy (Campania Region). METHODS: We performed a descriptive gender-related analysis of regional safety data, obtained from the spontaneous reporting system...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27860389/efficacy-and-safety-of-two-dosages-of-canrenone-as-add-on-therapy-in-hypertensive-patients-taking-ace-inhibitors-or-angiotensin-ii-receptor-blockers-and-hydrochlorothiazide-at-maximum-dosage-in-a-randomized-clinical-trial-the-escape-it-trial
#3
Giuseppe Derosa, Pamela Maffioli, Maria D'Avino, Carla Sala, Amedeo Mugellini, Vito Vulpis, Salvatore Felis, Luigina Guasti, Riccardo Sarzani, Alessandro Bestetti, Massimo Vanasia, Giovanni Gaudio
AIM: To evaluate the effects of canrenone as add-on therapy in patients already treated with angiotensin converting-enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) and hydrochlorothiazide at the maximum dosage (25 mg/day). METHOD: In this randomized, open label, controlled trial, we enrolled 175 Caucasian patients with essential hypertension not well controlled by concomitant ACE-I or ARBs and hydrochlorothiazide. At baseline 87 patients (57 males and 30 females) were randomized to add canrenone 50 mg, and 88 (56 males and 32 females) patients to canrenone 100 mg, once a day, for three months...
November 12, 2016: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/27859873/impact-of-an-intervention-on-the-prescription-of-aliskiren-after-new-evidence-on-safety-reported
#4
Isabel Rosich Martí, Alejandro Allepuz, Gemma Rodriguez Palomar, Francesca Ortin Font, Maria Soler Cera
PURPOSE: The purpose of the study is to analyze the impact of an intervention to disseminate safety alerts on the utilization of Aliskiren added to angiotensin converting enzyme inhibitor (ACEI) or an angiotensin-receptor blocker (ARB). METHODS: Quasi-experimental design (non-randomized intervention) comparing the utilization of Aliskiren + ACEI or ARB in a primary care area-intervention (PCA-I) with a primary care area-control (PCA-C) following a safety alert...
November 16, 2016: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/27829955/efficacy-and-safety-of-a-single-pill-fixed-dose-combination-of-azilsartan-and-amlodipine
#5
Kota Motozato, Shin-Ichiro Miura, Yuhei Shiga, Takaaki Kusumoto, Keijiro Saku
BACKGROUND: Guidelines for the management of hypertension recommend the use of drugs with different mechanisms of action in antihypertensive regimens that include single-pill fixed-dose combinations of medications. There is some controversy regarding which single-pill fixed-dose combinations of angiotensin II type 1 receptor blockers (ARBs) and calcium channel blockers (CCBs) are effective at reducing blood pressure (BP). METHODS: Forty hypertensive patients who were receiving a single-pill fixed-dose combination of valsartan 80 mg/day and amlodipine 5 mg/day or irbesartan 100 mg/day and amlodipine 5 mg/day were enrolled...
December 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27790455/efficacy-and-safety-of-complete-raas-blockade-with-aliskiren-in-patients-with-refractory-proteinuria-who-were-already-on-combined-ace-inhibitor-arb-and-aldosterone-antagonist
#6
Prabitha Panattil, M Sreelatha
INTRODUCTION: Proteinuria is always associated with intrinsic kidney disese and is a strong predictor of later development of End Stage Renal Disease (ESRD). As Renin Angiotensin Aldosterone System (RAAS) has a role in mediating proteinuria, inhibitors of this system are renoprotective and patients with refractory proteinuria are put on a combination of these agents. The routinely employed triple blockade of RAAS with Angiotensin Converting Enzyme (ACE) inhibitor, ARB and Aldosterone antagonist has many limitations...
September 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27777044/renin-angiotensin-aldosterone-system-inhibitors-in-hypertension-is-there-evidence-for-benefit-independent-of-blood-pressure-reduction
#7
REVIEW
Chirag Bavishi, Sripal Bangalore, Franz H Messerli
The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the pathogenesis of hypertension (HTN). Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are first line anti-HTN drug classes that are potent, effective and largely safe. Direct renin inhibitors (DRIs) have shown similar blood pressure (BP) reduction but more side effects. The efficacy of ACEIs and ARBs (for cardiovascular, cerebrovascular and renal protection) has been promoted to extend beyond what could be explained by BP reduction alone...
October 21, 2016: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/27774257/the-appropriate-dose-of-angiotensin-converting-enzyme-inhibitors-or-angiotensin-receptor-blockers-in-patients-with-dilated-cardiomyopathy-the-higher-the-better
#8
Junichi Ishida, Masaaki Konishi, Stephan von Haehling
Heart failure is a major public issue, and dilated cardiomyopathy (DCM) is one of the common etiologies of heart failure. DCM is generally progressive, and some patients with DCM need heart transplant despite optimal medical and mechanical therapy. Current guidelines recommend inhibitors of renin-angiotensin-aldosterone system, namely angiotensin-converting-enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), and mineralocorticoid receptor antagonist as well as beta-blockers for the medical treatment of heart failure with reduced ejection fraction, including DCM...
December 2015: ESC Heart Failure
https://www.readbyqxmd.com/read/27768266/procedures-for-the-handling-of-retaliation-complaints-under-section-1558-of-the-affordable-care-act-final-rule
#9
(no author information available yet)
This document provides the final text of regulations governing employee protection (retaliation or whistleblower) claims under section 1558 of the Affordable Care Act, which added section 18C to the Fair Labor Standards Act to provide protections to employees who may have been subject to retaliation for seeking assistance under certain affordability assistance provisions (for example, health insurance premium tax credits) or for reporting potential violations of the Affordable Care Act's consumer protections (for example, the prohibition on rescissions)...
October 13, 2016: Federal Register
https://www.readbyqxmd.com/read/27754075/os-18-07-safety-and-efficacy-of-arb-hctz-combination-therapy-in-controlling-morning-hypertension-in-very-elderly-patients
#10
Hiroki Uchiwa, Hisashi Kai, Yoshiko Iwamoto, Takahiro Anegawa, Yoshihiro Fukumoto
OBJECTIVE: Morning hypertension is an independent risk for cerebrovascular and cardiovascular events. Although the incidence of morning hypertension increases with age, treatment of morning hypertension has not been established particularly in late-elderly patients. Among various combinations, ARB combined with a small dose of thiazide diuretic is desirable because the two drugs have complementary mechanisms of action, and effectively reduce BP. Thus, we investigated the safety and efficacy of ARB/hydrochlorothiazide (HCTZ) combination in controlling morning hypertension in the very elderly...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27754017/br-04-3-development-of-new-angiotensin-receptor-blocker
#11
Seong-Choon Choe
There are several classes of anti-hypertensive agents in the world, the most recently developed agent is angiotensin receptor blocker (ARB). There are already 8 ARBs in the market, but still medical unmet need for treatment of hypertension is existed. The 'ideal' anti-hypertensive agent would have a number of characteristics: (1) effective in lowering blood pressure to recommend goals; (2) high efficacy as monotherapy; (3) rapid onset of effect; (4) convenient once-daily administration to maximize compliance; (5) sustained efficacy over 24 hours; (6) response increases with higher doses (clear dose-response effect); and (7) optimum tolerability profile...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27731574/azilsartan-novel-angiotensin-receptor-blocker
#12
Ramesh R Dargad, Jai D Parekh, Rohit R Dargad, Shweta Kukrety
OBJECTIVE: To describe the efficacy and safety profile of the new angiotensin receptor blocker (ARB), "Azilsartan Medoxomil", reviewing data available from both clinical and pre-clinical studies. MATERIAL: We completed a review of the English literature from PubMed using the keywords- azilsartan medoxomil, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEi) and hypertension. DATA EVALUATION: Many clinical trials have been conducted comparing the efficacy of azilsartan with other ARB's and also with the ACEi ramipril...
March 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27642996/os-18-07-safety-and-efficacy-of-arb-hctz-combination-therapy-in-controlling-morning-hypertension-in-very-elderly-patients
#13
Hiroki Uchiwa, Hisashi Kai, Yoshiko Iwamoto, Takahiro Anegawa, Yoshihiro Fukumoto
OBJECTIVE: Morning hypertension is an independent risk for cerebrovascular and cardiovascular events. Although the incidence of morning hypertension increases with age, treatment of morning hypertension has not been established particularly in late-elderly patients. Among various combinations, ARB combined with a small dose of thiazide diuretic is desirable because the two drugs have complementary mechanisms of action, and effectively reduce BP. Thus, we investigated the safety and efficacy of ARB/hydrochlorothiazide (HCTZ) combination in controlling morning hypertension in the very elderly...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27642928/br-04-3-development-of-new-angiotensin-receptor-blocker
#14
Seong-Choon Choe
There are several classes of anti-hypertensive agents in the world, the most recently developed agent is angiotensin receptor blocker (ARB). There are already 8 ARBs in the market, but still medical unmet need for treatment of hypertension is existed. The 'ideal' anti-hypertensive agent would have a number of characteristics: (1) effective in lowering blood pressure to recommend goals; (2) high efficacy as monotherapy; (3) rapid onset of effect; (4) convenient once-daily administration to maximize compliance; (5) sustained efficacy over 24 hours; (6) response increases with higher doses (clear dose-response effect); and (7) optimum tolerability profile...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27635180/depressor-and-anti-inflammatory-effects-of-angiotensin-ii-receptor-blockers-in-metabolic-and-or-hypertensive-patients-with-coronary-artery-disease-a-randomized-prospective-study-diamond-study
#15
Sen Adachi, Shin-Ichiro Miura, Yuhei Shiga, Tadaaki Arimura, Takashi Kuwano, Ken Kitajima, Amane Ike, Makoto Sugihara, Atsushi Iwata, Hiroaki Nishikawa, Natsumi Morito, Keijiro Saku
BACKGROUND: We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective, randomized clinical trial. METHODS: Forty-four hypertensive patients who had coronary artery disease (CAD) were enrolled. We randomly assigned patients to changeover from their prior angiotensin II receptor blockers (ARBs) to either azilsartan or olmesartan, and followed the patients for 12 weeks. RESULTS: Office systolic blood pressure (SBP) in the azilsartan group was significantly decreased after 12 weeks...
October 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27624701/varsity-medical-ethics-debate-2015-should-nootropic-drugs-be-available-under-prescription-on-the-nhs
#16
Emma Thorley, Isaac Kang, Stephanie D'Costa, Myrto Vlazaki, Olaoluwa Ayeko, Edward H Arbe-Barnes, Casey B Swerner
The 2015 Varsity Medical Ethics debate convened upon the motion: "This house believes nootropic drugs should be available under prescription". This annual debate between students from the Universities of Oxford and Cambridge, now in its seventh year, provided the starting point for arguments on the subject. The present article brings together and extends many of the arguments put forward during the debate. We explore the current usage of nootropic drugs, their safety and whether it would be beneficial to individuals and society as a whole for them to be available under prescription...
September 13, 2016: Philosophy, Ethics, and Humanities in Medicine: PEHM
https://www.readbyqxmd.com/read/27586538/leg-edema-with-s-amlodipine-vs-conventional-amlodipine-given-in-triple-therapy-for-hypertension-a-randomized-double-blind-controlled-clinical-trial
#17
Priyadarshani Galappatthy, Yasindu C Waniganayake, Mohomad I M Sabeer, Thusitha J Wijethunga, Gamini K S Galappatthy, Ruvan Ai Ekanayaka
BACKGROUND: Leg edema is a common adverse effect of dihydropyridine Calcium Channel Blockers (CCB) that may need dose reduction or drug withdrawal, adversely affecting the antihypertensive efficacy. Leg edema is reported to occur less often with (S)-amlodipine compared to conventional racemic amlodipine. We aimed to find the incidence of leg edema as a primary outcome and antihypertensive efficacy with (S)-amlodipine compared to conventional amlodipine. METHODS: This prospective, double-blind, controlled clinical trial randomized 172 hypertensive patients, not controlled on beta-blockers (BB) and angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), to either conventional amlodipine (5-10 mg; n = 86) or (S)-amlodipine (2...
2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/27557862/the-use-of-telmisartan-and-the-incidence-of-cancer
#18
Koray Tascilar, Laurent Azoulay, Sophie Dell'Aniello, Dorothee B Bartels, Samy Suissa
BACKGROUND: A meta-analysis reported an 8% increased risk of cancer with the use of angiotensin receptor blockers (ARBs), but subsequent meta-analyses and observational studies did not confirm this risk. However, telmisartan comprised 85% of the data in the original meta-analysis. Thus, the objective of this study was to determine whether the use of telmisartan, compared with other ARBs, is associated with an increased risk of cancer. METHODS: We used the United Kingdom Clinical Practice Research Datalink to assemble a cohort of all patients newly treated with ARBs between 2000 and 2008, and followed until December 2010...
August 24, 2016: American Journal of Hypertension
https://www.readbyqxmd.com/read/27536242/azilsartan-as-a-potent-antihypertensive-drug-with-possible-pleiotropic-cardiometabolic-effects-a-review-study
#19
REVIEW
Georgios Georgiopoulos, Vasiliki Katsi, Dimitrios Oikonomou, Georgia Vamvakou, Evangelia Koutli, Aggeliki Laina, Constantinos Tsioufis, Petros Nihoyannopoulos, Dimitrios Tousoulis
BACKGROUND: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). METHODS: Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety, and possible clinical role of AZL-M in hypertensive diabetic patients...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27511478/high-dose-calcium-channel-blocker-ccb-monotherapy-vs-combination-therapy-of-standard-dose-ccbs-and-angiotensin-receptor-blockers-for-hypertension-a-meta-analysis
#20
T He, X Liu, Y Li, X Y Liu, Q Y Wu, M L Liu, H Yuan
In this study, we evaluated the efficacy and safety of high-dose calcium channel blocker (CCB) monotherapy and standard-dose CCBs combined with angiotensin receptor blockers (ARBs) for patients with hypertension. A comprehensive search of PubMed, Embase and the Cochrane Central Register of Controlled Trials was performed in December 2015. Randomized controlled trials designed to identify the above goal were included. Thirteen trials including 2371 patients were identified. The standard-dose CCB/ARB combination resulted in a greater reduction of systolic blood pressure (WMD -2...
August 11, 2016: Journal of Human Hypertension
keyword
keyword
82037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"